MariTide: Amgen's Monthly GLP-1/GIP Antibody Conjugate
MariTide (maridebart cafraglutide) explained: a monthly GLP-1 agonist / GIP antagonist in trials, side-effect themes. Not medical advice.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Short answer
MariTide (maridebart cafraglutide) is Amgen's investigational obesity drug: an antibody that blocks the GIP receptor, joined to two GLP-1 agonist peptides. Unusually, it antagonises GIP where tirzepatide activates it, and it is being studied with monthly or less frequent injections. Phase 2 reported substantial weight loss with gastrointestinal side effects, especially early. Phase 3 (MARITIME) trials are ongoing; it is not approved. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
What users report here
Anonymous accounts are collected on the Tirzepatide reports. They are personal stories, often with other compounds in the mix, not evidence of effect.
Related topics
related peptides:
community guides:
More confessions from the archive
Community Q&A
- How is MariTide different from tirzepatide?
- Tirzepatide activates GIP and GLP-1 receptors. MariTide activates GLP-1 but blocks GIP, and is dosed far less often.
- Is MariTide approved?
- No. It is in phase 3 trials.
- Does this page give dosing advice?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.